Scientists test mRNA tech against seasonal flu in landmark safety trial
NCT ID NCT05446740
Summary
This was the first human study of a new mRNA-based flu vaccine candidate from GSK. It tested the safety and immune response of different doses in 324 healthy younger and older adults. The main goal was to see how well the body reacted to the vaccine and to identify any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Edegem, 2650, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Halifax, Nova Scotia, B3J 3G9, Canada
-
GSK Investigational Site
Sherbrooke, Quebec, J1L 0H8, Canada
-
GSK Investigational Site
Madrid, 28006, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Madrid, 28222, Spain
Conditions
Explore the condition pages connected to this study.